GlassScriptPhysician profile
Rakhi Patil
NPI 1740213495
$3,647.54
in general payments reported to CMS, 2019-2025
22 companies · $565 in 2025
The $565 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $255 · 2021: $533 · 2022: $341 · 2023: $865 · 2024: $624 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $613.37 | 2019-2022 | |
| Abbvie INC. | $568.31 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $350.44 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $339.36 | 2021-2025 | Clareon, Rocklatan, Tryptyr |
| Novartis Pharmaceuticals Corporation | $242.57 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $227.93 | 2019-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $187.52 | 2019-2021 | |
| Rxsight INC | $169.05 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Aerie Pharmaceuticals, INC. | $163.24 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $158.68 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $118.17 | 2023 | |
| Harrow Eye, LLC | $116.01 | 2023-2025 | Vevye |
| Thea Pharma INC. | $110.65 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $69.85 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ocular Therapeutix, INC. | $44.11 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $43.17 | 2022-2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $41.56 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $24.86 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $20.40 | 2019 | |
| Beaver-Visitec International, INC. | $17.24 | 2023 | |
| Tearlab Corp | $14.49 | 2024 | Scoutpro Osmolarity System |
| The Cameron-Ehlen Group, INC. | $6.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakhi Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.